Failure in Biological Technology
Navigation Links
Failure in Biological Technology
Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
CRANBURY, N.J., Aug. 4 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN ) announced today that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for its U.S. Patent Application Number 11/694,260, titled "Cyclic Natriuretic Peptide Constructs...SUNRISE, Fla., July 28 /PRNewswire-FirstCall/ -- Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and cardiovascular diseases announced today that the US FDA cleared a p...
Adenosine Regulation with GP531 Improves the Heart's Pumping Function in Dogs with Advanced Chronic Heart Failure NEW YORK, June 3 /PRNewswire/ -- PeriCor Therapeutics, Inc. announced today that positive preclinical results of its novel cardioprotective agent, GP531, were reported in a poster...
Nile Therapeutics CD-NP Clinical Program for Acute Heart Failure Released From Clinical Hold by FDA
SAN FRANCISCO, May 15 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, received notification from the U.S. Food and Drug Administration (FDA) that the agency has released the Company's CD-N...EAST BRUNSWICK, N.J., May 7 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) today announced that its biologics license application (BLA) for KRYSTEXXA (TM) (pegloticase), a novel biological drug for treatment failure gout (TFG) patients, will be reviewed by the Arthritis...
Disability and Poor Quality of Life Associated With Treatment Failure Gout Patients
New Study Published in the Journal of Rheumatology Examines Quality of Life and Disability in Treatment Failure Gout Patients EAST BRUNSWICK, N.J., May 5 /PRNewswire-FirstCall/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT ) announced today the print publication of the Savient-supported lo...European Trials Commencing for Injectable Biopolymer to Repair Weakened Heart Wall LAGUNA HILLS, Calif., April 14 /PRNewswire/ -- Symphony Medical, Inc., a developer of novel biopolymer therapies to cardiac abnormalities, announced today that its patented flagship technology, Algisyl-LVR(R), ...
Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID Trial) Demonstrated Safety and Biological Effects of SERCA2a Enzyme Replacement Using Gene Transfer SAN DIEGO, April 8 /PRNewswire/ -- Celladon Corporation today announced the publication of results ...
Cordex Pharma Forms Heart Failure Medical Advisory Board
Dr. Joshua Hare to Chair the Board LA JOLLA, Calif., Feb. 11 /PRNewswire-FirstCall/ -- Cordex Pharma, Inc. (OTC Bulletin Board: CDXP) announced today the formation of a Medical Advisory Board to provide clinical guidance for the Company's development program of CDP-1050 for the treatment of ...SAN FRANCISCO, Jan. 20 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), today announced that it will focus resources on the development of its natriuretic peptide franchise, including CD-NP which is in Phase II development for acute heart failure, and CU-NP which is a pre-clini...
WALTHAM, Mass., Dec. 26 /PRNewswire-FirstCall/ -- Interleukin Genetics, Inc. (NYSE Alternext US: ILI) announced today, that on December 23, 2008 the Company received notice from the NYSE Alternext US LLC (the "the Exchange") indicating that the Company is not in compliance with certain conditions ...
SAN MATEO, Calif., Nov. 3 /PRNewswire/ -- Top-line preliminary data from a Phase II/III clinical trial of Corthera's investigational drug relaxin for the treatment of acute heart failure will be presented next week at a satellite symposium at the American Heart Association's (AHA) Scientific S...
BROOMFIELD, Colo., Sept. 23 /PRNewswire/ -- ARCA biopharma, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) for the company's lead product candidate, bucindolol, an investigational and pharmacologically unique beta-blocker and mil...
Common Genetic Variations Predict Patient Response to Novel Beta Blocker Therapy TORONTO, Sept. 22 /PRNewswire/ -- Bucindolol, an investigational, pharmacologically unique beta-blocker and mild vasodilator, significantly reduces hospitalization and death among he...
- Company Will Request Hearing to Present Plans for Regaining Compliance - - NASDAQ Hearing Panel Has Discretion to Grant Peregrine Up to an Additional 180 Days to Regain Compliance - - Peregrine Currently Meets All Other NASDAQ Capital Market Initial Listing Requirements Ot...
Bioheart, Inc. to Introduce At-Home Heart Failure Monitor for Congestive Heart Failure Patients
Expands Focus to Include Intelligent Devices in Treatment of Heart Failure and Cardiovascular Diseases SUNRISE, Fla., July 10 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT ), a company committed to delivering intelligent devices and biologics that help monitor, di...Boston Scientific Announces FDA Approval of New Heart Failure Lead
ACUITY(R) Spiral lead has smallest left ventricular lead tip profile in the industry NATICK, Mass., May 16 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced U.S. Food and Drug Administration (FDA) approval of its ACUITY(R) Spiral...Boston Scientific Announces Japanese Approval of Heart Failure Lead
ACUITY(R) Steerable lead also receives reimbursement approval; Company plans to launch product immediately NATICK, Mass., April 14 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced Japanese Ministry of Health, Labor and Welfare (MHLW) appro...Boston Scientific Announces European Approval of New Heart Failure Lead
ACUITY(R) Spiral lead offers flexibility for placement in small, medium and large veins NATICK, Mass., March 3 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX ) today announced CE Mark approval of its ACUITY(R) Spiral left ventricular lead for use...PRINCETON, N.J., Dec. 21 /PRNewswire/ -- Otsuka Pharmaceutical Development & Commercialization, Inc. announced today that the U.S. Food and Drug Administration has accepted a new drug application (NDA) for the company's investigational oral once-daily medication tolvaptan, a selective V2-vasop...
Study Showed That NICOM can be Used to Accurately Measure Cardiac Output During Cardiopulmonary Exercise Testing (CPX) WASHINGTON, September 19 /PRNewswire/ -- Cheetah Medical Inc., developers of the Cheetah NICOM(TM) system, for non-invasive, real-time cardiac output monitoring, a...
GAITHERSBURG, Md., Sept. 11 /PRNewswire/ -- Ortho Biotech is pleased with recommendations of the Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) and Drug Safety and Risk Management Advisory Committee (DSRMAC) resulting from the Committees' evaluatio...
SAN FRANCISCO, Aug. 4 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a company focused on the development of novel therapeutics for heart failure patients, today announced dosing of its first patient in a Phase 2 clinical study of its lead product, CD-NP, for the treatme...
Nile Therapeutics Provides Update on Phase II CD-NP Clinical Trial for Acute Heart Failure
SAN FRANCISCO, March 27 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), a leading company in the development of novel therapeutics for heart failure patients, announced today that, in the course of reviewing the Investigational New Drug (IND) application materials that Nile ...Results of first clinical trial indicate pre-converted form of Coenzyme Q10 positively impacted heart function in critically ill subjects HOUSTON, Feb. 18 /PRNewswire/ -- Results from the first clinical trial evaluating ubiquinol's effects on late-stage congestive heart failure showed that th...
SAN FRANCISCO, Dec. 9 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), today announced preliminary data from its recently completed multi-center, open-label, ascending-dose Phase 1b clinical study of CD-NP, a novel chimeric natriuretic peptide, in patients with heart failure. R...
SAN MATEO‚ Calif.‚ Nov. 10 /PRNewswire/ -- Corthera Inc. today announced that an interim analysis of top-line data from Pre-RELAX-AHF, the Phase II portion of a Phase II/III multicenter, randomized, double-blind, international study, showed favorable efficacy and safety for relaxin, the compan...
TEMPE, Ariz., Oct. 16 /PRNewswire/ -- A team of researchers from Intrinsic Bioprobes Inc. has reported on a novel quantitative mass spectrometry immunoassay for the detection of bioactive B-type natriuretic peptide (BNP), in an article published online on Oct. 14 in the journal of Circulation:...
SAN FRANCISCO, Oct. 14 /PRNewswire-FirstCall/ -- Nile Therapeutics, Inc. (Nasdaq: NLTX ), today announced interim data from its multi-center, open-label Phase 2a clinical study of CD-NP, a novel chimeric natriuretic peptide, in patients hospitalized for acute heart failure. -- Statistica...
CRANBURY, N.J., Aug. 14 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN ) announced today the completion of a Phase 2a clinical trial of PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of heart failure (HF). The Phase...
Company Now Has Four Phase 2 Trials Underway MONTVALE, N.J., May 13 /PRNewswire-FirstCall/ -- Synvista Therapeutics, Inc. (Amex: SYI ) has dosed the first patient in a 160-patient Phase 2 study of alagebrium in patients with diastolic heart failure. BREAK (Beginning a Randomized...
CRANBURY, N.J., March 10 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN ) announced today the completion of a Phase I clinical trial of PL-3994, a novel, long-acting natriuretic peptide receptor A (NPRA) agonist under development for treatment of acute decompensated congestiv...
MISSISSAUGA, ON, Dec. 17 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN ; TSX:VAS) and Grupo Ferrer Internacional, S.A. ("Ferrer"), a leading European pharmaceutical and medical devices company, today announced the receipt of initial orders for Vasogen's Celacade(TM) System in Germany. Ce...
Router Failure and Software Crash UW-Madison Network
Madison, Wis. A network crash last week left many University of Wisconsin-Madison students, faculty and staff wondering just what exactly was wrong with their e-mail. The Division of Information Technology , which monitors and sustains the UWs networks, experienced a system-wide crash last Frid...Embracing failure is a necessary step for successful entrepreneurs
WHITEWATER Thomas Edison invented the electric light, the central power station, the phonograph and recorded 1,000 patents, but his effort to extract low-grade iron ore from sand cost him millions of dollars and was dubbed Edisons Folly in the late 1800s. Steve Jobs was fired by Apple Compu...Wisconsin's failure to attract federal defense dollars crimps tech economy
Economists love to compare the performance of Minnesota and Colorado to Wisconsin. Theyre similarly sized states, all removed from the East and West coasts, and each lays claim to being a high-tech haven. But the comparisons end when it comes to federal research spending on defense and aerospa...ThermoGenesis Announces Expanded Collaboration With Celling Technologies
...tors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortage...ntrol, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010 and 2010. A more c...Microbix Sales Grow 22% For Nine Months
...forth in the forward-looking statements including the risks associated with failure to get authorization to release Kinlytic for distribution in the US from th...iated with commercializing the pipeline technologies; risks associated with failure to develop and commercialize SST; non-adoption of SST; risks associated wit...GenVec Reports Second Quarter 2009 Financial Results
...differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the failure by GenVec to secure and maintain relationships with collaborators; risks relating t o certain of our product candidates being in early stages of de...ThermoGenesis Provides Update on Fiscal 2009 Results
...tors, including timing of FDA approvals, changes in customer forecasts, our failure to meet customers' purchase order and quality requirements, supply shortage...ntrol, could result in a materially different revenue outcome and/or in our failure to achieve the revenue levels we expect for fiscal 2010 and 2010. Revenue a...Other TagsAshesBreakthrouBreakthrouBreakthrouCHDOther Contentsshuttleshuttleshuttleshuttletubestubestubestubestubestubestubestubestubessievesimilaritysimilaritysimilaritysimilaritysimilaritymutationmutationmutationmutationmutationmutationmutationmutationmutationsilentsilentsilentsilentsimplesimplesimplesimplesimplesimplesimplesimplesimplesimple
(Date:12/4/2009)Scientists from the Royal Botanic Gardens, Kew and the Natural History Museum believe that carnivorous behaviour in plants is far more widespread than previously thought, with many commonly grown plan
(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
(Date:12/4/2009)A major discovery is challenging accepted thinking about amyloids the fibrous protein deposits associated with diseases such as Alzheimer,s and Parkinson,s and may open up a potential new area for t
Breaking Biology News(10 mins):Scientists think 'killer petunias' should join the ranks of carnivorous plants 2How nutrition affects healthy aging 2New therapy targets for amyloid disease 2American Hospital Management Company Announces the Opening of the New HOSPITAL UNIVERSITARIO DEL RIO HOSPIRIO in Cuenca Ecuador 48945 1American Hospital Management Company Announces the Opening of the New HOSPITAL UNIVERSITARIO DEL RIO HOSPIRIO in Cuenca Ecuador 48945 2New approach for treating recurrent prostate cancer on the horizon 48940 1New approach for treating recurrent prostate cancer on the horizon 48940 2New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases 4595 1New Legislation Seeks to Boost Participation in Clinical Trials for Rare Diseases 4595 2(Date:12/6/2009)... Volunteer organizations and members of the c...hcare System in West Los Angeles, will once again ...expected to soar to more than 5,000 veterans, acti... (PRWEB) December 6, 2009 -- V...y, in cooperation with the Greater VA Healthcare S...
(Date:12/5/2009)NEW ORLEANS, Dec. 5 There have been significant scientific advances in the field of blood cancers, and leading experts continue to gain a better understanding of how certain diseases progress in orde
(Date:12/5/2009)--In Youngest Babies, This Type of Blood Cancer Is Most Challenging-- ,, PHILADELPHIA and NEW ORLEANS, Dec. 5 Pediatric oncologists have identified specific genes, dubbed partner genes, that fuse w
(Date:12/5/2009)Research debunks the ,something,s wrong with being single, myth , , SATURDAY, Dec. 5 (HealthDay News) -- Pity the poor single people who pass their 40th birthday without ever tying the knot, s
(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation
Breaking Medicine News(10 mins):Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 2Health News:17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 2Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 3Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 4Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 5Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 6Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 7Health News:New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer 8Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 2Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 3Health News:New Gene Findings Will Help Guide Treatment in Infant Leukemia 4Health News:Never Married, Over 40, Well-Adjusted 2Health News:Never Married, Over 40, Well-Adjusted 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4[0] 17th Annual Event Honoring 5,000 + Veterans, Military Personnel to Include Real Life “Heroes” [0] New Research Demonstrates Advances in Optimizing Treatments and Quality of Life for People With Hard-To-Treat Forms of Blood Cancer[0] New Gene Findings Will Help Guide Treatment in Infant Leukemia[0] Never Married, Over 40, Well-Adjusted[0] AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |